Clinical trial
Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus…
NCT00002025 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00002025 |
|---|---|
| Title | Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient |
| Official title | Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Cytomegalovirus Infections, Cytomegalovirus Retinitis, HIV Infections |
| Intervention type | Drug |
| Interventions | Ganciclovir |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: